Compare Huntington Ingalls Industries Inc (HII) vs Pfizer Inc (PFE) Price & Performance

HII trades at $324.38, down 1.94% on the day, with a bullish technical signal supported by moving averages and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $5.27, exceeding expectations, and secured a $2.2 billion contract for surveillance capabilities (GlobeNewsWire, August 11, 2026). Valuation ratios include a P/E of 19.53 and P/S of 0.98, indicating reasonable pricing relative to earnings and sales.

Outlook remains positive due to contract wins and margin expansion, but risks include dependence on U.S. defense spending and competitive pressures. The consensus price target of $359.67 suggests upside potential, supported by 44% buy ratings from analysts.

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.